Nicolas Girard, MD, PhD

Continuing to implement prophylactic measures is necessary to maintain the benefit of subcutaneous amivantamab plus lazertinib in this NSCLC population.

Higher, durable rates of response to frontline therapy are needed to potentially improve long-term survival among patients with non–small cell lung cancer.

Nicolas Girard, MD, speaks with CancerNetwork® about the updated safety findings of nivolumab and chemotherapy in resectable non–small cell lung cancer.

In a conversation with CancerNetwork®, Nicolas Girard, MD, highlighted directions of future research with nivolumab and chemotherapy in patients with resectable non–small cell lung cancer.

In an interview with CancerNetwork®, Nicolas Girard, MD, discussed the rationale for assessing nivolumab and chemotherapy in resectable non–small cell lung cancer and the design of the phase 3 CheckMate 816 trial.

Nicolas Girard, MD, highlighted key findings from the CheckMate 816 trial, examining nivolumab and chemotherapy vs chemotherapy alone in resectable non–small cell lung cancer.